Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors
Assertio Holdings (Nasdaq: ASRT) has appointed Mark Reisenauer as an independent director to its Board of Directors, where he will serve on the Compensation Committee. Reisenauer brings over 30 years of experience in the biopharmaceutical industry, particularly in oncology and hematology. His previous role as President of U.S. Commercial at Astellas Pharmaceuticals saw him grow sales to nearly $5 billion while leading Marketing, Sales, Policy and Government Affairs, and Market Access teams.
The appointment aligns with Assertio's strategy to enhance its commercial platform and explore additional labeling, indication, and channel opportunities for existing products while seeking new commercial assets. Reisenauer's experience includes executive positions at Micromet Inc., Abbott Laboratories, Pharmacia , Bristol-Myers Squibb, and Zeneca Pharmaceuticals.
Assertio Holdings (Nasdaq: ASRT) ha nominato Mark Reisenauer come direttore indipendente nel suo Consiglio di Amministrazione, dove servirà nel Comitato per la Compensazione. Reisenauer porta con sé oltre 30 anni di esperienza nell'industria biofarmaceutica, in particolare in oncologia e ematologia. Nel suo precedente ruolo come Presidente della Divisione Commerciale negli Stati Uniti di Astellas Pharmaceuticals, è riuscito a far crescere le vendite a quasi 5 miliardi di dollari, guidando i team di Marketing, Vendite, Politiche e Affari Governativi, e Accesso ai Mercati.
La nomina è in linea con la strategia di Assertio di migliorare la sua piattaforma commerciale ed esplorare ulteriori opportunità di etichettatura, indicazione e canale per i prodotti esistenti, cercando al contempo nuovi asset commerciali. L'esperienza di Reisenauer include posizioni dirigenziali presso Micromet Inc., Abbott Laboratories, Pharmacia, Bristol-Myers Squibb e Zeneca Pharmaceuticals.
Assertio Holdings (Nasdaq: ASRT) ha nombrado a Mark Reisenauer como director independiente en su Junta Directiva, donde formará parte del Comité de Compensación. Reisenauer aporta más de 30 años de experiencia en la industria biofarmaceútica, especialmente en oncología y hematología. En su anterior cargo como Presidente de la División Comercial de EE. UU. en Astellas Pharmaceuticals, logró aumentar las ventas a casi 5 mil millones de dólares mientras lideraba los equipos de Marketing, Ventas, Políticas y Asuntos Gubernamentales, y Acceso al Mercado.
La designación se alinea con la estrategia de Assertio de mejorar su plataforma comercial y explorar oportunidades adicionales de etiquetado, indicación y canal para los productos existentes, al tiempo que busca nuevos activos comerciales. La experiencia de Reisenauer incluye cargos ejecutivos en Micromet Inc., Abbott Laboratories, Pharmacia, Bristol-Myers Squibb y Zeneca Pharmaceuticals.
Assertio Holdings (Nasdaq: ASRT)는 Mark Reisenauer를 독립 이사로 이사회에 임명하고, 보상위원회에서 활동할 예정입니다. Reisenauer는 생물제약 산업에서 30년 이상의 경험을 가지고 있으며, 특히 종양학과 혈액학 분야에서 두각을 나타냈습니다. Astellas Pharmaceuticals에서 미국 상업 부문 사장으로 재직할 당시, 그는 마케팅, 판매, 정책 및 정부 관계, 시장 접근 팀을 이끌며 판매를 거의 50억 달러로 성장시켰습니다.
이번 임명은 Assertio가 상업 플랫폼을 강화하고 기존 제품에 대한 추가 레이블링, 적응증 및 유통 기회 탐색을 위해 노력하며, 새로운 상업 자산을 모색하는 전략과 일치합니다. Reisenauer의 경험은 Micromet Inc., Abbott Laboratories, Pharmacia, Bristol-Myers Squibb 및 Zeneca Pharmaceuticals에서의 임원직을 포함합니다.
Assertio Holdings (Nasdaq: ASRT) a nommé Mark Reisenauer en tant que directeur indépendant au sein de son conseil d'administration, où il siègera au comité de rémunération. Reisenauer apporte plus de 30 ans d'expérience dans l'industrie biopharmaceutique, notamment en oncologie et hématologie. Dans son précédent rôle de président de la division commerciale des États-Unis chez Astellas Pharmaceuticals, il a réussi à faire passer les ventes à près de 5 milliards de dollars tout en dirigeant les équipes de marketing, de vente, de politique et d'affaires gouvernementales, ainsi que d'accès au marché.
Cette nomination s'inscrit dans la stratégie d'Assertio visant à améliorer sa plateforme commerciale et à explorer de nouvelles opportunités de marquage, d'indication et de canaux pour les produits existants, tout en recherchant de nouveaux actifs commerciaux. L'expérience de Reisenauer comprend des postes de direction chez Micromet Inc., Abbott Laboratories, Pharmacia, Bristol-Myers Squibb et Zeneca Pharmaceuticals.
Assertio Holdings (Nasdaq: ASRT) hat Mark Reisenauer als unabhängigen Direktor in seinen Vorstand berufen, wo er dem Vergütungsausschuss angehören wird. Reisenauer bringt über 30 Jahre Erfahrung in der biopharmazeutischen Industrie mit, insbesondere in der Onkologie und Hämatologie. In seiner vorherigen Rolle als Präsident des US-Commercial-Teams bei Astellas Pharmaceuticals verzeichnete er ein Umsatzwachstum auf nahezu 5 Milliarden Dollar, während er die Teams für Marketing, Vertrieb, Politik und Regierungsangelegenheiten sowie Marktzugang leitete.
Die Ernennung steht im Einklang mit der Strategie von Assertio, die kommerzielle Plattform zu erweitern und zusätzliche Etikettierungs-, Indikations- und Vertriebsmöglichkeiten für bestehende Produkte zu erkunden, während gleichzeitig nach neuen kommerziellen Vermögenswerten gesucht wird. Reisenauers Erfahrung umfasst Führungspositionen bei Micromet Inc., Abbott Laboratories, Pharmacia, Bristol-Myers Squibb und Zeneca Pharmaceuticals.
- Appointment of experienced pharmaceutical executive with proven track record of growing sales to $5B at Astellas
- Strategic addition to board with expertise in product launches and commercial capabilities
- Enhanced potential for exploring new product opportunities and market expansion
- None.
LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an independent director to the Company’s Board of Directors. Mr. Reisenauer will serve as a member of the Compensation Committee.
“Mark is a highly accomplished commercial leader in complex, competitive therapeutic areas who also brings extensive oncology and hematology product experience to our board,” said Heather Mason, Chair of Assertio. “His successful new product and indication launches have been grounded in an inclusive leadership style driven by communication, analysis, and partnership, all traits that are central to our strategy as we seek to build Assertio’s commercial platform.”
“I am excited to join Assertio’s Board as the Company works to grow and enhance the opportunities within its existing commercial base while also diversifying into additional pharmaceutical assets,” said Mr. Reisenauer. “I am particularly excited about opportunities to evaluate additional labeling, indication and channel opportunities for existing products while also seeking new commercial assets that can enhance or build upon the existing business.”
Mr. Reisenauer is an accomplished oncology and hematology biopharmaceutical executive with more than 30 years of experience building commercial capabilities and leading successful new product and indication launches. He previously served as President of U.S. Commercial at Astellas Pharmaceuticals Inc., where he grew sales to nearly
About Assertio
Assertio is a commercial pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients. We have built our commercial portfolio through acquisition or licensing of approved products. Our commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting, and trade and distribution. To learn more about Assertio, visit www.assertiotx.com.
Forward Looking Statements
Statements in this communication that are not historical facts are forward-looking statements that reflect Assertio’s current expectations, assumptions and estimates of future performance and economic conditions. These forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, future events or the future performance or operations of Assertio, including risks related to the subject matter of this communication and our ability to realize the benefits from our operating model, deliver or execute on our business strategy, including to expand or diversify our asset base and market reach and drive cash flows and growth, successfully integrate new assets, and explore new business development initiatives. All statements other than historical facts may be forward-looking statements and can be identified by words such as “anticipate,” “believe,” “could,” “design,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “imply,” “intend,” “may,” “objective,” “opportunity,” “outlook,” “plan,” “position,” “potential,” “predict,” “project,” “prospective,” “pursue,” “seek,” “should,” “strategy,” “target,” “would,” “will,” “aim” or other similar expressions that convey the uncertainty of future events or outcomes and are used to identify forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the control of Assertio, including the risks described in Assertio’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission (“SEC”) and in other filings Assertio makes with the SEC from time to time.
Investors and potential investors are urged not to place undue reliance on forward-looking statements in this communication, which speak only as of this date. While Assertio may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by applicable law.
Investor Contact
Matt Kreps, Managing Director
Darrow Associates
M: 214-597-8200
mkreps@darrowir.com
FAQ
Who is Mark Reisenauer and what role will he play at Assertio Holdings (ASRT)?
What is Mark Reisenauer's most significant achievement before joining ASRT's board?
How will Mark Reisenauer's appointment benefit Assertio Holdings (ASRT)?
What are the key strategic areas Mark Reisenauer will focus on at ASRT?
